Press Release – New York, NY – August 13, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC as joint bookrunners for the recently priced $10 million initial public offering of Nasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions.
The Laidlaw & Company team was led by Luke Kottke, Mathew Moschovas and Justin John.
The Craft Capital Management team was led by Stephen Kiront and Mackey McFarlane.
The SRFC team was led by partner Ross Carmel, with associates Tomer Magid and Benjamin Sklar.
